REGENXBIO develops gene therapies that use AAV vectors to deliver working genes into cells to treat disease. RGNX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for RGNX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in RGNX in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGNX is in one of them and how their past RGNX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About REGENXBIO
REGENXBIO is a biotechnology company based in Rockville, Maryland, that develops gene therapies. Its treatments use modified viruses called AAV vectors, which are designed to deliver working genes into cells. The company's own pipeline targets eye, muscle and nervous system diseases. It also licenses its vector platform to drugmakers such as AbbVie and Novartis, which develop treatments for their own patients.
